新闻Pharmaxis sold assets to Aptar Pharma on Aug 1st '22.In August 2022, AptarGroup Inc. acquired worldwide rights to the proprietary Orbital dry powder inhaler (DPI) from Pharmaxis Inc. for an undisclosed amount.
新闻Pharmaxis launches Phase IIa monotherapy study.Pharmaxis is conducting a Phase IIa monotherapy study in up to 24 patients with myelofibrosis with its drug candidate PXS-5505.
新闻Pharmaxis hires Hashan De Silva as non-executive director.Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) has strengthened its board through the appointment of experienced life sciences investment professional Hashan De Silva as a non-executive director.
